26 /100
MEDIUM RISK
Score updated Jul 13, 2026

BDTX — Black Diamond Therapeutics, Inc. Dilution Risk Tracker

Track BDTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BDTX — Get alerts when the score changes →

As of July 13, 2026, Black Diamond Therapeutics, Inc. (BDTX) has a DilutionWatch DilutionScore of 26/100, rated MEDIUM dilution risk. Black Diamond Therapeutics, Inc. has a market capitalization of $127.21M, 57.30M shares outstanding, 106 institutional holders tracked. Key dilution vectors include approximately 999 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
0
📊 Float Risk
5
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for BDTX.
🔔 Track BDTX — Get forecast alerts →

💹 Market Data

Market Cap$127.21M
Shares Outstanding57.30M
Float52.47M
Cash$30.07M
Debt$17.88M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 0.1% shares (2026Q1 vs prior)
106 institutional holders · 40.54M shares
#1 T. Rowe Price Investment Management, Inc. 10.56M shares
#2 NEA Management Company, LLC 4.45M shares
#3 ACADIAN ASSET MANAGEMENT LLC 2.35M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest4.50M
Days to Cover1.8
% of Float8.6%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Jul 07, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2020
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for BDTX Shareholders

Black Diamond Therapeutics, Inc. (BDTX) has a DilutionScore of 26/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for BDTX shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for BDTX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for BDTX alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track BDTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking BDTX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for BDTX
📊 BDTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 BDTX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.